Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

n, of which $8.5 million was related to cost sharing and $18.1 million was related to the Excess Amounts, which are due to be received during our quarter ending March 31, 2013. At June 30, 2012, the Company had $5.8 million due from Janssen related to cost sharing. At September 30, 2012, the Company had cash, cash equivalents and marketable securities of $286.1 million.

The Company expects to end calendar year 2013 with cash, cash equivalents and marketable securities of more than $225 million.

"Ibrutinib has demonstrated great clinical progress during this past year. Today we have a very solid development program in place with 5 Phase III trials initiated and several more trials to be started this year. We were honored to announce this past Tuesday that ibrutinib received Breakthrough Designation in two B-cell malignancies. We look forward to working with the FDA to bring this therapy to market in a timely manner," said Bob Duggan, CEO and Chairman of the Board. "Looking ahead, our goals for this year are star high as we are continuing to unfold our clinical program. With our partner Janssen, we are committed to a shared vision of patient friendly, body harmonious solutions intended to improve the quality of life, increase duration of life and resolve serious medical health care needs for patients."

Recent Developments & HighlightsBreakthrough Therapy Designation

The Breakthrough Therapy Designation is intended to expedite the development and review of a potential new drug for serious or life-threatening diseases where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation of a drug as a Breakthrough Therapy was enacted as part of the 2012 Food and Drug Administration Safety and Innovation Act.

Pharmacyclics, together
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014  AuraSense Therapeutics, the pioneer in developing ... regulatory and immunotherapeutic agents, announced today that ... Therapeutics, executive leadership team as chief financial ... to joining AuraSense Therapeutics, Mr. Snyder was ... of Cellular Dynamics International Inc., where he ...
(Date:7/23/2014)... -- Having the right people at the table for significant ... and achieving clinical and operational goals. The 22 nd ... 20-22, 2014, in San Diego , ... experts discussing how partnerships have positively impacted their objectives. ... Executive Officer of Cape Regional Medical Center located in ...
(Date:7/23/2014)... , July 23, 2014 ... company of Trendlines Agtech , announced it ... Israel,s leading agricultural thermoplastics applications ... Valentis,s technology combines nanocrystalline cellulose (NCC), a ... with additional nanoparticles to produce highly improved polymeric ...
(Date:7/23/2014)... regulated information -- UCB today announced an ... with positive topline results from the latest Phase ... designed to evaluate the efficacy and safety of ... titration) compared to placebo, as adjunctive treatment in ... fully controlled despite treatment with one or two ...
Breaking Biology Technology:AuraSense Therapeutics Appoints Biotechnology Veteran David S. Snyder as Chief Financial Officer 2MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7
... (NYSE:,DHR) announced that Executive Vice President and Chief ... the Robert W. Baird Industrial,Conference in Chicago, IL ... CST.,The audio will be simultaneously webcast on ... manufacturer of Professional,Instrumentation, Medical Technologies, Industrial Technologies and ...
... 4 Cambrex,Corporation (NYSE: CBM ) reports third quarter 2008 ... (Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO ), -- Sales increased 3.2% (-1.7% ... 2007. -- Adjusted EBITDA for the quarter was up $1.7 ... last year. -- Debt, net of cash was $92.0 million ...
... PRGO ; TASE) today announced that its Board of ... on December 16, 2008 to,shareholders of record on November ... represents a ten percent increase over $0.05 per share,paid ... a leading global healthcare supplier that develops,manufactures and distributes ...
Cached Biology Technology:Cambrex Reports Third Quarter 2008 Results 2Cambrex Reports Third Quarter 2008 Results 3Cambrex Reports Third Quarter 2008 Results 4Cambrex Reports Third Quarter 2008 Results 5Cambrex Reports Third Quarter 2008 Results 6Cambrex Reports Third Quarter 2008 Results 7Cambrex Reports Third Quarter 2008 Results 8Cambrex Reports Third Quarter 2008 Results 9Cambrex Reports Third Quarter 2008 Results 10Cambrex Reports Third Quarter 2008 Results 11Cambrex Reports Third Quarter 2008 Results 12Cambrex Reports Third Quarter 2008 Results 13Cambrex Reports Third Quarter 2008 Results 14
(Date:7/23/2014)... July 23, 2014 BioCatch, the ... announced today it has been named in Gartner,s Market ... Guide replaces Gartner,s well-known Magic Quadrant for Web Fraud ... as one of several vendors to deliver passive biometric ... become a standard feature of at least 30% of ...
(Date:7/23/2014)... increase in temperature around the world by 2050, according ... Panel on Climate Change (IPCC), may be advantageous to ... in the growth of forage plants such as ... grazing in tropical countries such as Brazil., The conclusion ... the Department of Biology at the Ribeiro Preto Faculty ...
(Date:7/23/2014)... bacterial group called SUP05 will play an increasingly important ... oceans as oxygen minimum zones expand, according to research ... National Academy of Sciences . , University of British ... fjord, Canada,s Saanich Inlet, to chart how microbial community ... study paints a very detailed picture of how SUP05 ...
Breaking Biology News(10 mins):BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 2BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 3An increase in temperature by 2050 may be advantageous to the growth of forage plants 2An increase in temperature by 2050 may be advantageous to the growth of forage plants 3An increase in temperature by 2050 may be advantageous to the growth of forage plants 4Research charts the ecological impact of microbial respiration in the oxygen-starved ocean 2
... experts have been calling for an improved database that ... conservation strategies. Botanists at the University of Bonn have ... the publication, in the Journal of Biogeography, of a ... arranged in 867 zones, known as ecoregions. "This makes ...
... Clinic researchers have found that the cause of chronic sinus ... not in the nasal and sinus tissue targeted by standard ... of Journal of Allergy and Clinical Immunology and are ... been thought worldwide about the origin of chronic sinus infection: ...
... A team of researchers at the Universitat Autònoma de ... The sensors have the same size and thickness as ... DNA chains to several minutes or a few hours, ... to many different tasks, ranging from paternity tests and ...
Cached Biology News:Scientists map the world for nature conservation 2Chronic Sinus Infection Thought To Be Tissue Issue, Mayo Clinic Scientists Show It's Snot 2New miniaturised chip dramatically reduces time taken for DNA analysis 2New miniaturised chip dramatically reduces time taken for DNA analysis 3
... Expression is a powerful application ... Utilising a novel interface, Expression makes ... incredibly simple. Expression uses the very ... standards in the way sequences are ...
... Mouse Antibody to Human Cytokeratin TYPE II ... (Type II) keratins. Including epidermal cell keratin ... 58kD, 65kD and 67kD. Broad keratin reactivity ... and cornea. Immunogen: ...
... XpressPack™ Colorimetric Detection System is intended for ... DNA generated by an in-house validated in ... target of interest. • ... is a hybridization capture assay designed to ...
Mouse Anti-Human Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 (KIR2DL4 Monoclonal Antibody Family: New...
Biology Products: